---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-012836"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2024-09-17T23:59:59+00:00"
generated_at: "2026-05-31T04:10:32.644402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Capricor signs binding term sheet with Nippon Shinyaku for European deramiocel rights; $15M equity + $20M upfront

## Summary
- Nippon Shinyaku to commercialize deramiocel in EU, UK and other European countries; Capricor receives double-digit revenue share.
- Up to $715M in milestone payments plus $20M upfront upon definitive agreement (expected Q4 2024); combined milestones now ~$1.5B.
- Private placement of 2.8M shares at $5.36 (20% premium to 60-day VWAP) raises ~$15M; proceeds extend cash runway into 2026.
- Capricor to develop and manufacture deramiocel; meeting with EMA planned to discuss European expansion.

## SEC filing metadata
- accession: 0001558370-24-012836
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2024-09-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837024012836/0001558370-24-012836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837024012836/capr-20240916x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-012836
- JSON: https://secwatch.observer/filing/0001558370-24-012836.json
- Plain text: https://secwatch.observer/filing/0001558370-24-012836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.